Case Study of Intrahepatic Combined Immunochemotherapy after Hepatic Resection for Four Patients with Liver Metastases from Colorectal Cancer

We performed intrahepatic combined immunochemotherapy (ACIT) after hepatic resection for patients with liver metastases from colorectal cancer to prevent recurrence in the liver. ACIT consists of 5 different agents, ie, recombinant interleukin-2 (IL-2), OK-432, adriamycin, cyclophosphamide and famot...

Full description

Saved in:
Bibliographic Details
Published inNippon Shokaki Geka Gakkai zasshi Vol. 26; no. 4; pp. 1072 - 1075
Main Authors Oka, Masaaki, Uchiyama, Tetsuji, Shimizu, Ryoichi, Yano, Kazuma, Nishida, Minekatsu, Hazama, Shoichi, Shimoda, Kouji, Suzuki, Michinari, Harada, Kikuo, Suzuki, Takashi
Format Journal Article
LanguageJapanese
Published The Japanese Society of Gastroenterological Surgery 1993
Subjects
hepatic resection
intrahepatic combined immunochemotherapy
liver metastases from colorectal cancer
Online AccessGet full text

Cover

More Information
Summary:We performed intrahepatic combined immunochemotherapy (ACIT) after hepatic resection for patients with liver metastases from colorectal cancer to prevent recurrence in the liver. ACIT consists of 5 different agents, ie, recombinant interleukin-2 (IL-2), OK-432, adriamycin, cyclophosphamide and famotidine. The survival rate of patients with ACIT (40-month survival rate; 100%) was higher than that of 9 patients without intrahepatic therapy (40-month survival rate; 45%). Natural killer activity was augmented significantly after ACIT. Thus, intrahepatic combined immunochemotherapy after hepatic resection for liver metastases from colorectal cancer may be worth performing in further clinical trial.
ISSN:0386-9768
1348-9372
DOI:10.5833/jjgs.26.1072